Literature DB >> 15291685

Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate.

X Henry Hu1, Scott A Bull, Enid M Hunkeler, Eileen Ming, Janelle Y Lee, Bruce Fireman, Leona E Markson.   

Abstract

BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are widely used as the first-line treatment for depression. Information regarding their side effects is mostly based on controlled clinical trials.
METHOD: Patients who received an SSRI for a new or recurrent case of depression (ICD-9 code 296.2 or 311) between December 15, 1999, and May 31, 2000 were interviewed by telephone 75 to 105 days after initiation of SSRI therapy. Using closed-ended questions, investigators asked patients if they experienced any of 17 side effects commonly associated with SSRIs, how bothersome they were, and what their duration was. Prescribing physicians completed a written survey providing their estimates about frequency of side effects associated with SSRIs and how bothersome those side effects are.
RESULTS: Of 401 patients who completed the phone interview, 344 patients (86%) reported at least 1 side effect, and 219 patients (55%) experienced 1 or more bothersome side effect(s). The most common bothersome side effects were sexual dysfunction and drowsiness (17% each). While most side effects first occurred within the first 2 weeks of treatment, the majority of patients were still experiencing the same side effects at the time of interview, most notably blurred vision (85%) and sexual dysfunction (83%). Overall, physicians (N = 137) significantly underestimated the occurrence of the 17 side effects explored, and they tended to underrate how bothersome those side effects were to their patients.
CONCLUSION: Side effects associated with SSRIs are common and bothersome to patients. Treatment-emergent side effects tend to persist during the first 3 months of treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15291685     DOI: 10.4088/jcp.v65n0712

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  59 in total

1.  Antidepressant and Antipsychotic Drugs.

Authors:  Andrew D Krystal
Journal:  Sleep Med Clin       Date:  2010-12-01

2.  Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction.

Authors:  Jeffrey R Bishop; Sharon S Chae; Shitalben Patel; Jessica Moline; Vicki L Ellingrod
Journal:  Psychiatry Res       Date:  2012-04-24       Impact factor: 3.222

Review 3.  Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly.

Authors:  Brian Draper; Karen Berman
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

4.  Management strategies for SSRI-induced sexual dysfunction.

Authors:  Sakina J Rizvi; Sidney H Kennedy
Journal:  J Psychiatry Neurosci       Date:  2013-09       Impact factor: 6.186

5.  Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report.

Authors:  Diane Warden; Madhukar H Trivedi; Stephen R Wisniewski; Benji Kurian; Sidney Zisook; Susan G Kornstein; Edward S Friedman; Sachiko Miyahara; Andrew F Leuchter; Maurizio Fava; A John Rush
Journal:  J Clin Psychopharmacol       Date:  2010-06       Impact factor: 3.153

Review 6.  Impact of Antidepressant Drugs on Sexual Function and Satisfaction.

Authors:  David S Baldwin; Chris Manson; Magda Nowak
Journal:  CNS Drugs       Date:  2015-11       Impact factor: 5.749

Review 7.  A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy.

Authors:  J Michael Bostwick
Journal:  Mayo Clin Proc       Date:  2010-04-29       Impact factor: 7.616

Review 8.  Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review.

Authors:  Shaheen E Lakhan; Karen F Vieira
Journal:  Nutr J       Date:  2010-10-07       Impact factor: 3.271

9.  Study of effects of selective serotonin reuptake inhibitors on stages of sexual function in Iranian patients with major depressive disorder.

Authors:  Mitra Safa; Saeid Sadr; Firouzeh Talischi; Fatemeh Ghasem Boroujerdi
Journal:  Ther Adv Psychopharmacol       Date:  2013-12

10.  Neurological and cardiovascular adverse events associated with antimanic treatment in children and adolescents.

Authors:  Jeanette M Jerrell
Journal:  CNS Neurosci Ther       Date:  2009-09-21       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.